Wilhelm M, Sprenger K B, Vossas U, Ohnesorge F K
J Toxicol Clin Toxicol. 1987;25(3):209-20. doi: 10.3109/15563658708992625.
Aluminum (Al) loading due to administration of human albumin (HA) solutions was studied in 2 patients with stable renal function who underwent plasma exchange once (patient A) and twice (patient B) per week for treatment of hyperviscosity syndrome. Al was determined by Zeeman-AAS in plasma before, during and after treatment, also in bone of one patient and in various preparations of HA from different manufacturers. In addition, the net Al uptake (difference between total Al influx and efflux) and the 24th urinary excretion between 2 exchanges were determined. The electrolyte solution used for dilution had no detectable Al, while HA contained between 15 and 1900 micrograms Al/l. Increase of Al in plasma after treatment was clearly related to Al content of the HA used. When the patients received substitution solutions based on inadvertently highly Al contaminated 20% HA (1419 micrograms/l), the average net uptake was 2265 in patient A and 2049 micrograms in patient B and plasma Al rose from 8.4 respectively 18.0 before to 69.2 and 86.5 micrograms/l after treatment. By using medium Al contaminated HA (574 micrograms/l), the net uptake was 742 (pat. A) and 819 micrograms (pat.B), and there was an elevation of plasma Al from 5.1 respectively 18.2 to 34.2 and 39.8 micrograms/l. Following a net uptake of 870 micrograms patient A excreted 668 micrograms Al until the next treatment (23% positive balance). Treating patient A with a low Al HA (47 micrograms/l), there was a slight increase of plasma Al from 10.8 to 16.2 micrograms/l, the net Al uptake was negligible (less than 10 micrograms), and the weekly Al balance was negative. After 10 months of plasma exchange therapy (patient A) there was no increase of Al in bone (6.4 micrograms/g). We conclude, that the use of HA with a low Al contamination is recommended for all patients receiving this therapy during chronic intermittent plasma exchange or for other indications, especially in cases with impaired renal function.
对2例肾功能稳定的患者进行了研究,他们因高粘滞综合征接受每周1次(患者A)和每周2次(患者B)的血浆置换治疗,在此期间观察了人血白蛋白(HA)溶液给药导致的铝(Al)负荷情况。在治疗前、治疗期间和治疗后,通过塞曼原子吸收光谱法(Zeeman-AAS)测定血浆中的铝,还对其中1例患者的骨骼以及不同厂家生产的各种HA制剂进行了测定。此外,还测定了净铝摄取量(总铝流入量与流出量之差)以及两次置换之间的24小时尿铝排泄量。用于稀释的电解质溶液中未检测到铝,而HA中的铝含量在15至1900微克/升之间。治疗后血浆中铝的增加与所用HA的铝含量明显相关。当患者接受基于意外高度铝污染的20%HA(1419微克/升)的替代溶液时,患者A的平均净摄取量为2265微克,患者B为2049微克,血浆铝分别从治疗前的8.4和18.0微克/升升至治疗后的69.2和86.5微克/升。使用中等铝污染的HA(574微克/升)时,净摄取量为742(患者A)和819微克(患者B),血浆铝从5.1和18.2微克/升分别升至34.2和39.8微克/升。在净摄取870微克铝后,患者A在下一次治疗前排泄了668微克铝(正平衡为23%)。用低铝HA(47微克/升)治疗患者A时,血浆铝从10.8微克/升略有增加至16.2微克/升,净铝摄取量可忽略不计(小于10微克),每周铝平衡为负。血浆置换治疗10个月后(患者A),骨骼中的铝没有增加(6.4微克/克)。我们得出结论,对于所有在慢性间歇性血浆置换期间接受该治疗或因其他适应症接受治疗的患者,尤其是肾功能受损的患者,建议使用低铝污染的HA。